Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-27
2007-02-27
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10436100
ABSTRACT:
This invention is directed to compounds that provide for sustained systemic concentrations of GABA analogs following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 5084479 (1992-01-01), Woodruff
patent: 5563175 (1996-10-01), Silverman et al.
patent: 6001876 (1999-12-01), Singh
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6103932 (2000-08-01), Horwell et al.
patent: 6117906 (2000-09-01), Silverman et al.
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/37296 (1999-07-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/23067 (2000-04-01), None
patent: WO 00/31020 (2000-06-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 01/20331 (2001-03-01), None
patent: WO 02/00209 (2002-01-01), None
patent: WO 02/28411 (2002-04-01), None
patent: WO 02/32376 (2002-04-01), None
patent: WO 02/100344 (2002-12-01), None
A. Tsuji et al., “Carrier-Mediated Intestinal Transport of Drugs,”Pharmaceutical Research, vol. 13, No. 7, 1996, pp. 963-977.
F.H. Leibach et al., “Peptide transporters in the Intestine and the Kidney,”Annu. Rev. Nutr., vol. 16, 1996, pp. 99-119.
M.A. Navia et al., “Design principles for orally bioavailable drugs,”DDT, vol. 1, No. 5, 1996, pp. 179-189.
H. Wang et al., “Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain,”Am. Physiological Society, 1998, pp. C967-C975.
S. A. Adibi, “The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function,”Gastroenterology, vol. 113, 1997, pp. 332-340.
S.T. Dieck et al., “The peptide transporter PepT2 is expressed in Rat Brain and Mediates the Accumulation of the . . . ”,GLIA, vol. 25, 1999, pp. 10-20.
R.K. Verma et al., “Osmotically Controlled Oral Drug Delivery,”Drug Development and Industrial Pharmacy, vol. 26, No. 7, 2000, pp. 695-708.
Fosker & Law, “L-Glutamyl-Gamma-Aminobutyric Acid and Related Compounds”,J. Chem. Soc., 1965, pp. 7305-5312.
Nielsen et al., “Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media”,Journal of Controlled Release, May 18, 2001, vol. 73, No. 1, pp. 21-30.
Lee et al., “Pharmacogenomics of drug transporters: the next drug delivery challenge”,Advanced Drug Delivery Reviews, Oct. 1, 2001, vol. 50, No. Suppl. 1.
EPO Annex to Form PCT/ISA/206 Communication Relating to the Results of the Partial International Search mailed Nov. 14, 2003.
Barrett Ronald W.
Cundy Kenneth C.
Gallop Mark A.
Scheuerman Randall A.
Teller Roy
Tsang Cecilia J.
XenoPort
LandOfFree
Amino acid conjugates providing for sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid conjugates providing for sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid conjugates providing for sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880083